Novak Financial Planning LLC Cuts Stock Position in Becton, Dickinson and Company (NYSE:BDX)


Share on StockTwits

Novak Financial Planning LLC lessened its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,653 shares of the medical instruments supplier’s stock after selling 61 shares during the quarter. Novak Financial Planning LLC’s holdings in Becton, Dickinson and were worth $888,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. Alpha Omega Wealth Management LLC raised its stake in shares of Becton, Dickinson and by 0.6% during the fourth quarter. Alpha Omega Wealth Management LLC now owns 8,004 shares of the medical instruments supplier’s stock worth $2,003,000 after purchasing an additional 44 shares during the last quarter. Private Asset Management Inc. grew its holdings in Becton, Dickinson and by 3.3% during the first quarter. Private Asset Management Inc. now owns 1,368 shares of the medical instruments supplier’s stock worth $333,000 after acquiring an additional 44 shares during the period. Verdence Capital Advisors LLC grew its holdings in Becton, Dickinson and by 1.8% during the fourth quarter. Verdence Capital Advisors LLC now owns 2,572 shares of the medical instruments supplier’s stock worth $644,000 after acquiring an additional 45 shares during the period. Valeo Financial Advisors LLC grew its holdings in Becton, Dickinson and by 3.6% during the fourth quarter. Valeo Financial Advisors LLC now owns 1,350 shares of the medical instruments supplier’s stock worth $338,000 after acquiring an additional 47 shares during the period. Finally, Central Bank & Trust Co. grew its holdings in Becton, Dickinson and by 2.4% during the fourth quarter. Central Bank & Trust Co. now owns 2,048 shares of the medical instruments supplier’s stock worth $512,000 after acquiring an additional 48 shares during the period. Institutional investors and hedge funds own 83.22% of the company’s stock.

A number of research analysts recently weighed in on BDX shares. Raymond James upped their price objective on Becton, Dickinson and from $270.00 to $282.00 and gave the stock an “outperform” rating in a report on Friday, January 29th. Morgan Stanley raised Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $262.00 to $297.00 in a report on Tuesday, December 15th. Wells Fargo & Company lowered Becton, Dickinson and from an “overweight” rating to an “equal weight” rating and set a $265.00 target price on the stock. in a report on Tuesday, December 15th. Citigroup upped their target price on Becton, Dickinson and from $273.00 to $280.00 and gave the company a “neutral” rating in a report on Friday, February 5th. Finally, Piper Sandler upped their target price on Becton, Dickinson and from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, February 4th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $281.08.

Shares of NYSE:BDX opened at $247.93 on Monday. The company has a quick ratio of 1.07, a current ratio of 1.54 and a debt-to-equity ratio of 0.72. Becton, Dickinson and Company has a 52-week low of $219.50 and a 52-week high of $284.97. The stock’s fifty day simple moving average is $243.16 and its 200-day simple moving average is $243.72. The company has a market capitalization of $72.04 billion, a P/E ratio of 90.82, a P/E/G ratio of 2.34 and a beta of 0.79.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.14 by $1.41. Becton, Dickinson and had a return on equity of 13.30% and a net margin of 5.11%. The business had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $4.87 billion. During the same period in the prior year, the business earned $2.65 earnings per share. The business’s revenue was up 25.8% on a year-over-year basis. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.5 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 31st. Stockholders of record on Wednesday, March 10th were given a $0.83 dividend. The ex-dividend date was Tuesday, March 9th. This represents a $3.32 annualized dividend and a dividend yield of 1.34%. Becton, Dickinson and’s dividend payout ratio is currently 32.55%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Should I invest in “strong buy” stocks?

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.